Intellia Therapeutics (NASDAQ:NTLA) Trading Down 8.2% After Analyst Downgrade

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price was down 8.2% on Thursday after HC Wainwright lowered their price target on the stock from $30.00 to $25.00. HC Wainwright currently has a buy rating on the stock. Intellia Therapeutics traded as low as $13.09 and last traded at $13.1140. Approximately 7,207,754 shares were traded during trading, an increase of 35% from the average daily volume of 5,327,713 shares. The stock had previously closed at $14.28.

A number of other research firms have also weighed in on NTLA. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Leerink Partners set a $35.00 target price on Intellia Therapeutics in a research note on Monday, April 27th. Citigroup reiterated an “outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 28th. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, March 2nd. Finally, reiterated a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.25.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Intellia Therapeutics and maintained a $25 price target, implying substantial upside versus the current share price. The firm also reiterated estimates that reflect continued losses but a path toward improvement. Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright
• Neutral Sentiment: HC Wainwright’s forecast updates for Q1 2027, Q2 2027, and FY2027 were broadly in line with the company’s loss-making profile, suggesting analysts still expect Intellia to burn cash but do not see a major near-term fundamental surprise.
• Neutral Sentiment: Wedbush reaffirmed a Hold/Neutral view on NTLA, reinforcing the market’s wait-and-see stance ahead of key clinical and commercial milestones. Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
• Negative Sentiment: HC Wainwright cut its price target from $30 to $25, which can weigh on sentiment even though the stock still has implied upside from that target.
• Negative Sentiment: Brookline Capital Markets lowered earnings estimates for multiple periods, including Q3 2026, Q4 2026, and FY2026, signaling softer expected profitability and adding to the cautious analyst backdrop.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently made changes to their positions in NTLA. Farallon Capital Management LLC bought a new stake in Intellia Therapeutics during the third quarter valued at about $10,486,000. SG Americas Securities LLC boosted its holdings in Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock worth $2,264,000 after acquiring an additional 92,485 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Intellia Therapeutics by 1.8% in the third quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock worth $190,744,000 after acquiring an additional 192,651 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in Intellia Therapeutics in the third quarter worth about $23,519,000. Finally, Contrarius Group Holdings Ltd boosted its holdings in Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -3.69 and a beta of 1.93. The firm has a fifty day simple moving average of $13.65 and a two-hundred day simple moving average of $12.07.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter last year, the company earned ($1.10) earnings per share. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.38 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.